Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Payables (2016 - 2025)

Vistagen Therapeutics' Payables history spans 12 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Payables rose 61.69% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, up 61.69%, while the annual FY2025 figure was $653000.0, 57.79% down from the prior year.
  • Payables for Q4 2025 was $1.7 million at Vistagen Therapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Payables topped out at $2.7 million in Q3 2021 and bottomed at $1800.0 in Q4 2021.
  • The 4-year median for Payables is $1.4 million (2025), against an average of $1.5 million.
  • The largest YoY upside for Payables was 627.46% in 2021 against a maximum downside of 98.48% in 2021.
  • A 4-year view of Payables shows it stood at $1800.0 in 2021, then skyrocketed by 96400.0% to $1.7 million in 2023, then crashed by 40.18% to $1.0 million in 2024, then surged by 61.69% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Payables are $1.7 million (Q4 2025), $2.5 million (Q3 2025), and $1.4 million (Q2 2025).